Brief: U.S. FDA Grants PV-10 Orphan Drug Designation For Neuroblastoma
05/11/2018 13:04
Nov 5 (Reuters) - Provectus Biopharmaceuticals Inc
PVCT.PK :
* US FDA GRANTS PV-10 ORPHAN DRUG DESIGNATION FOR
NEUROBLASTOMA
Source text for Eikon: ID:nGNX8LSV32
Further company coverage: PVCT.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting